Viking Therapeutics (VKTX) Tops Q1 EPS by 2c

Viking Therapeutics (NASDAQ: VKTX) reported Q1 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09).

"The progress and momentum we achieved during 2018 have continued into 2019," stated Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. "At the recent EASL conference, we announced positive new data from our Phase 2 trial of VK2809 in patients with fatty liver disease and hypercholesterolemia demonstrating impressive efficacy at doses as low as 5 mg daily. Even at these lower exposures, VK2809 shows potent liver fat reduction and improvements in plasma lipids that are on par with the previously reported 10 mg doses. These data provide further evidence that VK2809's unique liver-targeted mechanism may lead to enhanced tissue exposures, allowing for greater flexibility in dosing. In addition, VK2809's predictable PK, encouraging safety, and excellent tolerability continue to indicate an exciting therapeutic profile in the setting of NASH. The observed reduction in LDL-C and other lipids also suggests potential cardiovascular benefits, an important consideration in this patient population. We remain on track to initiate a Phase 2b study of VK2809 in biopsy-confirmed NASH later this year."

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• West Pharma (WST) Tops Q1 EPS by 26c, provides guidance
• TAL Education (TAL) Tops Q1 EPS by 10c